- Home
- LUD vs WHWK Comparison
LUD vs WHWK Comparison
Compare LUD & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUD
- WHWK
- Stock Information
- Founded
- LUD 2004
- WHWK 2007
- Country
- LUD Hong Kong
- WHWK United States
- Employees
- LUD N/A
- WHWK N/A
- Industry
- LUD
- WHWK Biotechnology: Pharmaceutical Preparations
- Sector
- LUD
- WHWK Health Care
- Exchange
- LUD NYSE
- WHWK Nasdaq
- Market Cap
- LUD 96.7M
- WHWK 87.6M
- IPO Year
- LUD 2025
- WHWK N/A
- Fundamental
- Price
- LUD $5.63
- WHWK $1.95
- Analyst Decision
- LUD
- WHWK
- Analyst Count
- LUD 0
- WHWK 0
- Target Price
- LUD N/A
- WHWK N/A
- AVG Volume (30 Days)
- LUD 38.7K
- WHWK 119.3K
- Earning Date
- LUD 01-01-0001
- WHWK 08-15-2025
- Dividend Yield
- LUD N/A
- WHWK N/A
- EPS Growth
- LUD N/A
- WHWK N/A
- EPS
- LUD N/A
- WHWK 0.91
- Revenue
- LUD $44,863,430.00
- WHWK $27,775,000.00
- Revenue This Year
- LUD N/A
- WHWK $49.83
- Revenue Next Year
- LUD N/A
- WHWK N/A
- P/E Ratio
- LUD N/A
- WHWK $2.13
- Revenue Growth
- LUD N/A
- WHWK 16.51
- 52 Week Low
- LUD $3.40
- WHWK $1.21
- 52 Week High
- LUD $9.52
- WHWK $3.81
- Technical
- Relative Strength Index (RSI)
- LUD N/A
- WHWK N/A
- Support Level
- LUD N/A
- WHWK N/A
- Resistance Level
- LUD N/A
- WHWK N/A
- Average True Range (ATR)
- LUD 0.00
- WHWK 0.00
- MACD
- LUD 0.00
- WHWK 0.00
- Stochastic Oscillator
- LUD 0.00
- WHWK 0.00
About LUD LUDA TECHNOLOGY GROUP LIMITED
Luda Technology Group Ltd is a company that is principally engaged in the manufacture and sale of stainless steel and carbon steel flanges and fittings products and trading of steel pipes, valves, and other steel tubing products.
About WHWK Whitehawk Therapeutics Inc. Common Stock
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.